Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goser
详细信息    查看全文
文摘

Aims

The treatment of intermediate- to high-risk prostate cancer with radical radiotherapy is usually in combination with neoadjuvant androgen deprivation therapy. The aim of the present trial was to investigate whether degarelix achieves comparable efficacy with that of goserelin plus bicalutamide as neoadjuvant therapy before radiotherapy.

Materials and methods

The study was a randomised, parallel-arm, active-controlled, open-label trial in 244 men with a UICC prostate cancer TNM category T2b-T4, N0, M0, Gleason score ¡Ý7, or prostate-specific antigen ¡Ý10?ng/ml and a total prostate volume >30?ml, who were scheduled to undergo radical radiotherapy and in whom neoadjuvant androgen deprivation therapy was indicated. Eligible patients received treatment with either monthly degarelix (240/80?mg) or goserelin (3.6?mg) for 12 weeks, the latter patients also receiving bicalutamide (50?mg) for 17 days initially. The primary efficacy measure was the mean percentage reduction in total prostate volume from baseline at week 12 measured by transrectal ultrasound. The severity and relief of lower urinary tract symptoms were assessed by the International Prostate Symptom Score questionnaire. Quality of life was assessed by the eighth question of the International Prostate Symptom Score. About 50 % of the patients had moderate to severe lower urinary tract symptoms at baseline.

Results

The total prostate volume decreased significantly from baseline to week 12 in both treatment groups, reaching ?36.0?¡À?14.5 % in degarelix-treated patients and ?35.3?¡À?16.7 % in goserelin-treated patients (adjusted difference: ?0.3 % ; 95 % confidence interval: ?4.74; 4.14 % ). At the end of the therapy, more degarelix- than goserelin-treated patients reported International Prostate Symptom Score decreases of ¡Ý3 points (37 % versus 27 % , P?=?0.21). In addition, in patients with a baseline International Prostate Symptom Score of ¡Ý13, the magnitude of the decrease was larger in degarelix- (n?=?53) versus goserelin-treated patients (n?=?17) (6.04 versus 3.41, P?=?0.06).

Conclusions

The efficacy of degarelix in terms of prostate shrinkage is non-inferior to that of goserelin plus bicalutamide. The added benefits of degarelix in terms of more pronounced lower urinary tract symptom relief in symptomatic patients could be the reflection of differences in the direct effects on extra-pituitary receptors in the lower urinary tract [Clinicaltrials.gov ID: NCT00833248].

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700